Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …

Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the
incidence has increased worldwide. Risk factors include increased longevity, obesity …

The importance and role of the estrogen receptor (ER) pathway have been well-recognized
in both breast cancer development and progression. The treatment of choice in women with …

The global burden of cancer has recorded an ever-increasing trend in the developing world.
The GLOBOCAN, 2018 report has ranked breast cancer (BC) as the second (11.6%) most …

Although similar phenotypically, there is evidence that male and female breast cancer differ
in their molecular landscapes. In this systematic review, we consolidated all existing …

Simple Summary Male breast cancer is a rare disease, representing around 0.5% of the
malignances in men. Although they receive the same treatment as women with breast …

Simple Summary The role of gender in oncology is an issue that is starting to be recognized
as being of extreme importance in the last few years. While breast cancer is commonly …

Male breast cancer (MBC) presents problems with identification of high-risk groups. Risk
factors include hepatic dysfunction, high ambient working temperature, exposure to exhaust …

Abstract Purpose CompLEEment-1 (NCT02941926) is a single-arm, open-label, multicentre
phase IIIb study investigating the safety and efficacy of ribociclib plus letrozole (RIB+ LET) in …

Purpose CompLEEment-1 is a phase 3b trial in an expanded patient population with
hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative …